Oncology
Cancer Cells Evolve, So Does Our Science
We employ a multi-pronged approach by modulating two or more ‘hallmark’ mechanisms simultaneously |
 |
This approach guides our choice of molecular targets and our pipeline of novel cancer medicines |
To know more about our assets targeting these multiple hallmarks of cancer, visit our Pipeline Page
The PI3K Journey
Tracing Our Journey in Identifying and Developing Key Assets in the PI3K Space
- Early Efforts
- Pioneering Research
- Global Outlook
- Expanding Horizons
- Regulatory Progress
- Regional Deals
- Future Steps
Early Efforts
Early programs in the PI3K space hit safety issues; Rhizen sees opportunity for safer, differentiated molecules.
Pioneering Research
Development & optimization of leads in PI3K space; Rhizen’s R&D team overcomes liabilities of earlier efforts
Global Outlook
Licensing deal with TG Therapeutics (pre-clinical stage): Program moves into the clinic for B cell lymphomas
Expanding Horizons
Rhizen leverages existing Expanding Horizons; Differentiated asset Tenalisib starts pre-clinical journey
Regulatory Progress
Maturation of our alliances with TG Therapeutics; Umbralisib poised for success – NDA Filed with US FDA.
Regional Deals
Rhizen signs a deal with
Curon Biopharma for Greater China
rights of Tenalisib.
Future Steps
footprint in ROW while partnering
in developed markets
Our PI3K Assets
Onco Inflammation
Cancer and Inflammatory Processes and Targets Are Often Linked, so is Our Opportunistic/Licensing Focus
To know more about our Onco-Inflammation licensing opportunities, visit our Pipeline Page
Clinical Trials
ID |
Title |
Status |
Conditions |
Locations |
|---|---|---|---|---|
Safety and Efficacy of Tenalisib (RP6530) in Combination With |
Recruiting |
T Cell Lymphoma |
United States |
|
Compassionate Use Study of Tenalisib (RP6530) |
Recruiting |
Hematological |
Poland/Georgia/ |
|
Efficacy and Safety of Tenalisib (RP6530) in Patients With |
Recruiting |
CLL |
Poland/Bulgaria/Georgia |
|
Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K |
Concluded |
Non Hodgkin |
United States, |
|
Safety and Efficacy Study of RP4010, in Patients With Relapsed |
Concluded |
Lymphoma |
United States, |
|
Safety and Efficacy Study of a Dual PI3K Delta/Gamma |
Concluded |
PTCL, CTCL |
United States |
|
Safety, Tolerability and Pharmacokinetics of Oral Doses of RP3128 of Rhizen Pharmaceuticals |
Concluded |
Healthy Volunteers |
Canada |
|
|
|
Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL |
Concluded |
Classical Hodgkin |
United States |
Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies |
Concluded |
B- Cell Lymphoma, |
Italy/France |
|
To Evaluate the Food Effect on Relative Bioavailability of |
Concluded |
Healthy Volunteers |
Canada |
Scientific Advisory Board
Dr. James E. Sanders, DVM, PhD, DABT
as a staff pathologist in the U.S. Army at Walter Reed Army Institute of Research and from 1981 to 1987 as a Veterinary Pathologist at Merck, Sharp and Dohme. Joined Rhône-Poulenc Rorer as Director of Toxicology in 1987 and continued through mergers (Aventis, Sanofi Aventis) until 2005. Here, as Global Head of Toxicology, had worldwide responsibilities for designing and implementing the nonclinical toxicology and safety pharmacology testing of all drug candidates developed by the company. Was responsible for the preparation of the nonclinical sections for all INDs, NDAs, CTXs, and MAAs and for the communications with government Health Authorities globally. From 2005 to 2007 was Senior Director at Johnson & Johnson, directing development of pharmaceuticals from early development through NDA and MAA approval including government Health Authority interface. In these positions, has represented his company externally in forums and working parties such as the CPMP’s SWP, DIA, ILSI, Toxicology Forum, ICH and PhRMA. Attended Ohio State University gaining a DVM, an MS in Pharmacology and a PhD in toxicology. Is certified by the American Board of Toxicology and is a member of the SOT, and the Society of Toxicological Pathologists.
Dr. T. S. Ganesan M.D, Ph.D
He completed his training in Medical Oncology at St. Bartholomew’s Hospital, London. His doctorate was on Philadelphia chromosome positive leukemias that was awarded by the University of London. He was subsequently appointed as Consultant Medical Oncologist at Churchill Hospital, Oxford and established a laboratory as Clinical Scientist at the Weatherall Institute of Molecular Medicine, Oxford. After 15 years at Oxford he was appointed as Chairman, Cancer Institute and Institute of Molecular Medicine at Amrita Institute of Medical Sciences, Cochin, India towards the end of 2005. His research interests have been on cancer genetics and signal transduction, in addition to clinical trials. The research in UK was supported initially by the Imperial Cancer Research Fund and subsequently by Cancer Research UK. In India, the research is supported by Department of Biotechnology and Indian Council of Medical Research. He has been awarded the Clinical Excellence award in UK during his tenure there. He has over 100 papers to his credit in international journals.
Dr. Dhanapalan Nagarathnam Ph.D
cancer indications, diabetes, autoimmune disorders, HCV, anti-bacterial, inflammatory bowel disease (IBD), etc. Prior to this, Dr. Nagarathnam was the Director of Medicinal Chemistry at Pharmasset, Princeton, NJ, wherein he directed the HCV drug discovery projects and played a key role in selecting three liver-targeted clinical candidates and the most advanced candidate is in Phase-III human trials, and the company was later acquired by Gilead in 2012. Dr. Nagarathnam also worked as Principal Research Scientist-II at Bayer HealthCare, West Haven, CT, in multiple oncology, diabetes, obesity and osteoporosis projects and Synaptic Pharmaceutical Corporation (currently Lundbeck), Paramus, NJ on multiple human GPCR-targeted projects targeting BPH, pain, obesity, etc. In the Synaptic/Merck collaboration project he contributed to nomination of two alpha-1a adrenoceptor selective candidates for the treatment of Benign Prostatic Hyperplasia (BPH).Dr. Nagarathnam has over 25 years of experience in pharmaceutical industry and this includes leadership role in project management, medicinal chemistry, combinatorial chemistry, high-throughput synthesis, lead generation, lead optimization, process research, production, and business development. Dr. Nagarathnam obtained his Ph. D. in Organic Chemistry from the University of Madras, India and conducted postdoctoral research in Medicinal Chemistry at University of California, Purdue University, and University of Illinois and process research at Malti-Chem Research Center. Overall, Nagarathnam is an inventor on over 50 issued patents/patent applications, and an author of over 75 peer-reviewed publications in leading journals and conference presentations.
